Oncoliq develops a blood-based liquid-biopsy test that detects microRNAs elevated in early tumor development and uses machine-learning models to interpret results. The company reports a 90% sensitivity for its first product, Oncoliq Breast, based on its public data and already has revenue. Founded by researchers Marina Simian and Adriana de Siervi, Oncoliq plans to launch Oncoliq Mama as a Laboratory Developed Test toward the end of 2025 and to seek ANMAT approval in Argentina followed by FDA submission for the U.S. market. The startup’s strategy emphasizes a decentralized, low-cost, scalable approach to extend diagnostic access across Latin America. Its roadmap and preliminary validation underpin its current seed fundraising and positioning for future, larger clinical-stage financings.

Total raised

$3M

Funding rounds

2

Latest round

Seed

Latest activity

Jul 2026